Benefits of Referring Your Patients
At Lung Research Florida, led by Dr. Frank Hull, we understand the challenges you face in managing patients with difficult-to-treat respiratory conditions. By referring eligible patients to our research studies, you can:
-
Access to Cutting-Edge Treatments
Offer your patients opportunities to receive novel therapies not yet available through standard care, potentially years before these treatments reach the market.
-
Comprehensive Care at No Cost
Your patients receive extensive monitoring, diagnostic testing, and treatment at no cost, while maintaining their relationship with you as their primary physician.
-
Continuity of Care
We work as an extension of your practice, keeping you informed of your patient's progress and returning them to your care after study completion.
-
Advance Medical Knowledge
Contribute to the development of new treatment options for challenging respiratory conditions, ultimately benefiting all patients.
-
Referral Fee Program
We offer a $200 referral fee for each patient who meets criteria and completes screening. Our staff can also assist with pre-screening patients in your office.
Quick Referral Options
Call Our Referral Line
Fax a Referral
954-523-8569
Online Referral Form
Prefer a paper form?
Download Referral Form (PDF)Current Clinical Trials Accepting Referrals
The following trials are currently open for enrollment. Click on each trial for detailed eligibility criteria.
Key Inclusion Criteria
- Ages: 40-80 years
- COPD diagnosis: Post-bronchodilator FEV1/FVC ratio < 70%
- Smoking history: ≥ 10 pack-years (current or former)
- Blood eosinophil count: ≥ 100 cells/mm³
- CAT score: ≥ 10 (phlegm and cough items ≥ 2 each)
- Cardiovascular criteria (must meet at least one):
- Established CV disease (min. 50% of participants)
- Combination of 3 out of 5 CV risk factors
- High CV risk score on validated assessment tool
- Significant coronary artery calcification with additional risk factor
Key Exclusion Criteria
- Use of maintenance inhaled corticosteroid (ICS) treatment more than 2 months within the past 12 months
- Active asthma diagnosis within past 5 years
- End-stage renal disease or eGFR < 20 mL/min/1.73 m²
- Recent heart/lung transplant or listing
- Unstable or life-threatening cardiac disease
- Recent pneumonia or moderate/severe COPD exacerbation
Key Inclusion Criteria
- Ages: 18-80 years
- Persistent cough for ≥ 1 year prior to screening
- Diagnosis of Refractory/Unexplained Chronic Cough (RCC/UCC):
- Insufficient improvement after treatment for underlying conditions, OR
- Unexplained cough with no evidence of underlying condition
- Eligibility Adjudicator confirmation of RCC diagnostic criteria
- Cough Severity VAS ≥ 40 mm at screening and Day 1
- Chest X-ray or CT thorax within 5 years showing no significant abnormality
Key Exclusion Criteria
- Current smoker or quit < 6 months ago
- Smoking history ≥ 20 pack-years
- Diagnosis of COPD, bronchiectasis, idiopathic pulmonary fibrosis, or other significant respiratory disorders
- Uncontrolled asthma
- Incomplete cough evaluation for gastroesophageal reflux or rhinitis
Key Inclusion Criteria
- Ages: 18-85 years
- Clinical history consistent with non-cystic fibrosis bronchiectasis (NCFB):
- Cough
- Chronic sputum production and/or recurrent respiratory infections
- Confirmed by recent chest CT scan (≤ 5 years old)
- Mucopurulent sputum producers with a history of chronic expectoration
- Pulmonary Exacerbations (PEs) in the past 12 months:
- At least 2 moderate PEs OR 1 severe PE
- If on maintenance antibiotics, at least one exacerbation while on therapy
Key Exclusion Criteria
- Bronchiectasis due to:
- Cystic fibrosis
- Hypogammaglobulinemia
- Common variable immunodeficiency
- Known active nontuberculous mycobacteria (NTM) lung infection
- Pulmonary fibrosis
- Current tobacco smokers or smoking cessation < 6 months prior to screening
- Known or suspected immunodeficiency disorder
Key Inclusion Criteria
- Ages: ≥ 40 years
- COPD diagnosis: ≥ 1 year prior to enrollment
- Lung function:
- Post-bronchodilator FEV1/FVC < 0.70
- Post-bronchodilator FEV1 > 20% of predicted normal value
- Exacerbation history (within 12 months):
- ≥ 2 moderate exacerbations OR ≥ 1 severe exacerbation
- At least one treated with systemic corticosteroids
- Occurred while on stable maintenance therapy
- Stable dose of optimized inhaled maintenance therapy for ≥ 3 months
- Smoking history: ≥ 10 pack-years
- CAT total score ≥ 10 with phlegm and cough items each scored ≥ 2
Key Exclusion Criteria
- Current diagnosis of asthma or other significant respiratory conditions
- Known alpha-1 antitrypsin deficiency
- History of lung volume reduction surgery or lung transplantation
- Need for long-term oxygen therapy (≥ 12 hours per day)
- Active pulmonary infection or tuberculosis
- Clinically significant bronchiectasis
Home Sleep Apnea Testing
In addition to our pulmonary clinical trials, we offer convenient home sleep testing services for your patients with suspected sleep apnea.
Our Sleep Study Services
Under the direction of Dr. Frank Hull, board-certified in Sleep Medicine, we offer:
- Alice NightOne (Level 3 Device) - $200
- Monitors Nasal Pressure/Flow, Snoring, Position, Respiratory Effort, and Pulse Oximetry
- Patient picks up the recording device and returns it the next day
- WatchPAT One (Pulse Arterial Tone Disposable Device) - $300
- Measures PAT Signal, Tracheal Airflow, Snoring, Position, and Pulse Oximetry
- Requires smartphone for companion application download and Bluetooth to device
- Can be picked up or mailed to the patient; no return required (disposable/recyclable)
Timely Results & Comprehensive Support
All studies are scored and interpreted by Dr. Hull. Final sleep study reports are faxed back to the referring physician within 3 business days. We can also help with:
- Obtaining DME (CPAP/BiPAP) for patients who fail PAP therapy
- Evaluation for alternative therapies like the Inspire Device hypoglossal nerve stimulator (Obstructive Sleep Apnea) and the Remede Device diaphragmatic pacemaker (Central Sleep Apnea)
Alice NightOne
Level 3 Device with comprehensive monitoring capabilities
WatchPAT One
Innovative disposable device with smartphone integration
Online Physician Referral Form
Complete this secure form to refer a patient to our clinical trials program.
Questions About Referring a Patient?
Our team is available to provide more information about our clinical trials and discuss specific patient cases.